Jove
Visualize
Contact Us

Related Experiment Videos

alpha(1)-blockers for BPH: are there differences?

C de Mey1

  • 1ACPS, Mainz-Kastel, Germany. CdeMey@T-online.de

European Urology
|November 24, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Ambroxol Lozenges in the Treatment of Acute Uncomplicated Sore Throat - a Pooled Analysis.

Drug research·2016
Same author

Efficacy and Safety of an Oral Ambroxol Spray in the Treatment of Acute Uncomplicated Sore Throat.

Drug research·2015
Same author

A multi-centre, randomised, double-blind, placebo-controlled clinical trial on the efficacy and tolerability of GeloMyrtol® forte in acute bronchitis.

Drug research·2013
Same author

Bioequivalence of a novel minitablet formulation of levetiracetam.

Arzneimittel-Forschung·2012
Same author

Nanotechnologic biosensor ellipsometry and biomarker pattern analysis in the evaluation of atherosclerotic risk profile.

Biosensors & bioelectronics·2008
Same author

Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in humans.

Clinical pharmacology and therapeutics·2001
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Alpha-blockers effectively treat lower urinary tract symptoms (LUTS) from benign prostatic obstruction (BPO). Tamsulosin offers superior cardiovascular safety and tolerability compared to other alpha-blockers, making it a preferred choice for LUTS management.

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Alpha-blockers are established treatments for lower urinary tract symptoms (LUTS) associated with benign prostatic obstruction (BPO).
  • While clinical efficacy is similar across alpha-blockers, significant differences exist in their cardiovascular safety and tolerability profiles.
  • Understanding the selectivity of alpha-blockers for specific adrenoceptor subtypes is crucial for optimizing treatment outcomes.

Purpose of the Study:

  • To evaluate the clinical efficacy and cardiovascular safety of various alpha-blockers in treating LUTS suggestive of BPO.
  • To explore the relationship between pharmacological selectivity (alpha(1A/1D) vs. alpha(1B) blockade) and clinical outcomes.
  • To identify alpha-blocker treatment regimens that maximize urological benefit while minimizing cardiovascular risks.

Main Methods:

Related Experiment Videos

  • Comparative analysis of clinical efficacy and cardiovascular safety data for different alpha-blockers.
  • In vitro assessment of adrenoceptor subtype selectivity (pharmacological selectivity).
  • In vivo evaluation of functional selectivity differentiating urological and cardiovascular effects.

Main Results:

  • Alpha-blockers efficacious in hypertension (doxazosin, terazosin, alfuzosin) may impair blood pressure control in normotensive LUTS patients.
  • Tamsulosin demonstrates minimal impact on elevated blood pressure and orthostatic blood pressure control compared to placebo.
  • Tamsulosin, 0.4 mg once daily without dose titration, is convenient, effective, and associated with low cardiovascular risk.

Conclusions:

  • Tamsulosin exhibits high clinical selectivity, offering a favorable cardiovascular safety profile for LUTS management.
  • Treatment regimens, including dosage and patient interactions, significantly influence clinical selectivity and safety.
  • Tamsulosin represents a highly convenient and safe option for patients with LUTS due to BPO.